New acne pill tested for Long-Term safety in 240 patients

NCT ID NCT06248008

Completed Disease control Sponsor: Ascletis Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the long-term safety of a daily pill called ASC40 (Denifanstat) in 240 people with moderate to severe acne who had already completed a previous phase 3 trial. Participants took the drug once daily for up to 40 weeks, with regular blood tests and checkups to monitor for side effects. The main goal was to see how many people experienced treatment-related problems, not to measure how well the drug cleared acne.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASC40 (Denifanstat) tablets
What this could lead to: If successful, this could confirm that ASC40 is safe for long-term use, potentially offering a new daily pill option for managing moderate to severe acne.
What could go wrong: This is an extension study focused on safety, not on proving how well the drug works. Side effects or lack of lasting benefit may limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACNE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACNE

Contacts and locations

Locations

Huashan Hospital Fudan University

Shanghai, Shanghai Municipality, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.